My Size (MYSZ) Upgraded to Buy: Here's What You Should Know

Zacks upgraded My Size, Inc. (MYSZ) to a Zacks Rank #2 (Buy) after analysts raised the Zacks Consensus EPS estimate by 5.9% over the past three months. The consensus for fiscal year ending December 2025 stands at -$2.54 per share, unchanged from the prior year, and Zacks notes the upgrade places the stock in its top 20% by estimate revisions — a positioning the firm says could drive buying pressure and near-term share appreciation.

Analysis

Market structure: The Zacks-driven upgrade to MYSZ (earnings estimate up 5.9%, FY2025 EPS still -$2.54) will likely attract short-term momentum buyers and small-cap growth funds but won’t change fundamental supply of its product or cash runway; winners are momentum/quant funds and option sellers collecting premium, losers are unprofitable small-caps lacking estimate support. Competitive dynamics favor large AI/measurement incumbents only if MYSZ converts interest into contracts; absent that, pricing power remains weak and any institutional inflow is ephemeral. Cross-asset: expect small-cap equity ETFs to see transient inflows, modest compression in IG credit spreads if risk-on extends, and option vol to rise around any follow-up news; FX and commodities unaffected materially.

Risk assessment: Tail risks include a rapid liquidity squeeze at MYSZ if cash runway <12 months, regulatory/privacy scrutiny on measurement tech, or a failed product validation—each could trigger >50% downside. Timing: immediate (days) — headline-driven pops and elevated intraday vol; short-term (1–3 months) — volatility around earnings/partnerships; long-term (>3 quarters) — requires positive revenue trajectory to justify re-rating. Hidden deps: concentrated analyst coverage and low float amplify moves; second-order effect is retail-driven gamma forcing. Catalysts: quarterly results, strategic partner announcements, or cash raises will accelerate or reverse the trend.

Trade implications: Direct tactical play is small, option-hedged exposure to MYSZ (6-month call spread) to capture headline-driven upside while capping downside; core overweight should be in NVDA and large-cap cloud (MSFT, GOOGL) for structural AI exposure. Pair trades: long NVDA vs short small-cap momentum basket (including MYSZ) to capture structural alpha; use options to express asymmetric risk. Entry/exit: act on current momentum within 2–6 trading days for MYSZ, scale NVDA/Cloud positions over 1–3 months with rebalancing at +/-20% moves.

Key Decisions for Investors

• Establish a tactical 0.5–1.0% portfolio long in MYSZ via a 6-month call spread (buy ATM, sell ~40% OTM) to cap downside; target 40–60% gross upside and cut exposure if MYSZ issues a cash-raise or price drops >30% from entry.
• Increase core AI/semiconductor exposure: add 1.0–2.0% to NVDA via 12–18 month LEAP calls (or staggered 6–12 month call spreads) to capture structural secular demand; trim if NVDA rallies >25% in 30 days or implied vol spikes >40% above historical.
• Implement a relative-value pair: long NVDA (1.0% notional) / short MYSZ (0.5% notional) to express structural winner vs headline momentum — use equal-dollar sizing and mark-to-market daily with stop-loss at 20% adverse move.
• Reduce aggregated small-cap momentum exposure by 1–2% and redeploy to MSFT or GOOGL (0.5–1% each) for durable cloud+AI cashflow; re-evaluate within 60–90 days around earnings and any announced partnerships.
• Monitor three specific catalysts in next 30–60 days before increasing MYSZ: (1) cash runway disclosure >=12 months, (2) >+5% revenue/contract growth QoQ, (3) a named strategic partner. Exit or flip bias if none are met.